Showing posts with label cisplatin. Show all posts
Showing posts with label cisplatin. Show all posts

Sunday, November 25, 2012

Optimal dose of dasatinib determined for advanced, recurrent ovarian cancer


Optimal dose of dasatinib determined for advanced, recurrent ovarian cancer

Nov 2012

A phase I trial determined that dasatinib 150 mg daily is the optimum dose when dasatinib is combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.
Dasatinib is an oral SRC-family tyrosine kinase inhibitor. It has promising potential to treat advanced ovarian cancer because the SRC families play a role in the increased activation of cell migration, proliferation, survival, invasion, and angiogenesis. The SRC pathways are frequently dysregulated in solid tumors and can increase chemotherapy resistance.
Previous laboratory studies with ovarian cancer cell lines found that SRC inhibition enhanced the cytotoxic efficacy of both paclitaxel and cisplatin. Studies done in vivo found decreased tumor growth with SRC inhibition. This study sought to determine the maximum tolerated dose of dasatinib when it was combined with paclitaxel and cisplatin.
Administering dasatinib with paclitaxel did not alter the effects of either drug, according to the study's results. Further, dasatinib may be better used in combination with chemotherapy agents for a synergistic effect.
“It may also be better to combine dasatinib with only one cytotoxic therapy to improve tolerability,” study co-author Robert M. Wenham, MD, of the Moffitt Cancer Center explained.
The researchers concluded that finding biomarkers to direct the use of targeted therapies is of the utmost importance. Although SRC gene expression was not correlated with response, the research team found several differentially regulated genes between responders and those with stable disease.
“Unfortunately, a biomarker was unable to be identified to demonstrate which women are most likely to benefit from dasatinib,” said study contributor Johnathan M. Lancaster, MD, PhD, also of Moffitt Cancer Center. “Further study should explore relevant biomarkers and identify a patient population most likely to benefit from the addition of dasatinib.”
This study was published in Clinical Cancer Research (2012; doi:10.1158/1078-0432.CCR-12-0507).

Oncology Nurse Advisor

Thursday, October 18, 2012

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast andovarian cancer.


BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast andovarian cancer.


Oct 2012

Source

Cancer Epigenetics and Biology Program; Bellvitge Biomedical Research Institute; Barcelona, Catalonia Spain.

Abstract


Germline mutations in the BRCA1 or BRCA2 genes are associated with an increased risk of breast and ovarian cancer development. Both genes are involved in DNA repair, and tumors harboring genetic defects in them are thought to be more sensitive to DNA-damaging agents used in chemotherapy. However, as only a minority of breast and ovarian cancer patients carry BRCA1 or BRCA2 mutations, few patients are likely to benefit from these pharmacogenetic biomarkers. Herein, we show that, in cancer cell lines and xenografted tumors, BRCA1 CpG island promoter hypermethylation-associated silencing also predicts enhanced sensitivity to platinum-derived drugs to the same extent as BRCA1 mutations. Most importantly, BRCA1 hypermethylation proves to be a predictor of longer time to relapse and improved overall survival in ovarian cancerpatients undergoing chemotherapy with cisplatin.